Krystal Biotech, Inc. (KRYS) on Decifer

Decifer ranks KRYS number 64 of 270 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 34% a year and profits grew 127% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• It trades about 24% above similar companies, and its growth does not yet back up that price.
• Revenue growing 34% and profits up 127% are strong, but no clean read on management, no funded role, and a price about 21% above peers hold it back.

The current read

The evidence on KRYS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full KRYS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.